Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease

Pediatric Blood and Cancer

Volumn 61, Issue 3, 2014, Pages 479-487

  Simko, Stephen J ^a   Tran, Huy D ^a   Jones, Jeremy ^a   Bilgi, Mrinalini ^a   Beaupin, Lynda Kwon ^b   Coulter, Don ^c   Garrington, Timothy ^d   Mccavit, Timothy L ^e   Moore, Colin ^d   Rivera Ortegón, Francisco ^f   Shaffer, Linda ^g   Stork, Linda ^h   Turcotte, Lucie ⁱ   Welsh, Esperanza C ^j   Hicks, M John ^a   Mcclain, Kenneth L ^a   Allen, Carl E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f Hospital San Jose Tec de Monterrey   (Mexico)

^g UTHealth Austin Dell Children's Medical Center   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^j Centro de Especialidades Medicas   (Mexico)

more..

Author keywords

Clofarabine; Histiocytosis; Juvenile xanthogranuloma; Langerhans cell histiocytosis; Rosai Dorfman disease

Indexed keywords

CLADRIBINE; CLOFARABINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; METHOTREXATE; PREDNISONE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; BLADDER CATHETERIZATION; BONE MARROW BIOPSY; BRAIN BIOPSY; CERVICAL LYMPHADENOPATHY; CHILD; CLINICAL ARTICLE; CONGENITAL HYDROCEPHALUS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMOPHAGOCYTIC SYNDROME; HUMAN; INFANT; JUVENILE XANTHOGRANULOMA; LANGERHANS CELL HISTIOCYTOSIS; LEG PAIN; MALE; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENT DISEASE; REMISSION; SALVAGE THERAPY; SCHOOL CHILD; SINUS HISTIOCYTOSIS; SKULL INJURY; THROMBOCYTE TRANSFUSION; URETHRITIS; VOMITING; WEIGHT REDUCTION; YOUNG ADULT;

CLOFARABINE; HISTIOCYTOSIS; JUVENILE XANTHOGRANULOMA; LANGERHANS CELL HISTIOCYTOSIS; ROSAI-DORFMAN DISEASE;

ADENINE NUCLEOTIDES; ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; CHILD; CHILD, PRESCHOOL; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HISTIOCYTOSIS, SINUS; HUMANS; INFANT; MALE; RECURRENCE; SALVAGE THERAPY; XANTHOGRANULOMA, JUVENILE;

EID: 84892549084     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24772     Document Type: Article

References (26)

1. Allen CE, Li L, Peters TL, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 2010; 184:4557-4567.
2. Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010; 156:873-881, 881.e1.
3. Allen CE, McClain KL. Langerhans cell histiocytosis: A review of past, current and future therapies. Drugs Today (Barc) 2007; 43:627-643.
4. Kudo K, Ohga S, Morimoto A, et al. Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant 2010; 45:901-906.
5. Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood 2013; 121:5006-5014.
6. Ronceray L, Potschger U, Janka G, et al. Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: Effect on course and outcome. J Pediatr 2012; 161:129-133, e121-e123.
7. Weitzman S, Braier J, Donadieu J, et al. 2′-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer 2009; 53:1271-1276.
8. Imamura T, Sato T, Shiota Y, et al. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: A nationwide survey in Japan. Int J Hematol 2010; 91:646-651.
9. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41:2682-2689.
10. Egeler RM, de Kraker J, Voute PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: Experience at a single institution. Med Pediatr Oncol 1993; 21:265-270.
11. Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 2006; 107:613-619.
12. Apollonsky N, Lipton JM. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. J Pediatr Hematol Oncol 2009; 31:53-56.
13. Stover DG, Alapati S, Regueira O, et al. Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer 2008; 51:130-133.
14. Horneff G, Jurgens H, Hort W, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): Response to methotrexate and mercaptopurine. Med Pediatr Oncol 1996; 27:187-192.
15. Tasso M, Esquembre C, Blanco E, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer 2006; 47:612-615.
16. Aouba A, Terrier B, Vasiliu V, et al. Dramatic clinical efficacy of cladribine in Rosai-Dorfman disease and evolution of the cytokine profile: Towards a new therapeutic approach. Haematologica 2006; 91:ECR52.
17. Rodriguez-Galindo C, Jeng M, Khuu P, et al. Clofarabine in refractory Langerhans cell histiocytosis. Pediatr Blood Cancer 2008; 51:703-706.
18. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991; 51:2386-2394.
19. Berg SL, Bonate PL, Nuchtern JG, et al. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res 2005; 11:5981-5983.
20. Jeha S, Kantarjian H. Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther 2007; 7:113-118.
21. Hijiya N, Barry E, Arceci RJ. Clofarabine in pediatric acute leukemia: Current findings and issues. Pediatr Blood Cancer 2012; 59:417-422.
22. Abraham A, Alsultan A, Jeng M, et al. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatr Blood Cancer 2013; 60:E19-E22.
23. Minkov M, Grois N, McClain K, et al., Histiocyte Society Evaluation and Treatment Guidelines, April 2009. www.histiocytesociety.org/document.doc?id=290 Accessed June 1, 2013.
24. Blouin P, Yvert M, Arbion F, et al. Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA-AraC. Pediatr Blood Cancer 2010; 55:757-760.
25. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105:940-947.
26. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 2004; 42:438-444.